Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trialDiana Crivellari, Aron Goldhirsch, Kathryn P. Gray et al.|The Breast|2013Cited by 56
124P Risk stratification in HR+/HER2- EBC: A comparative study of Prosigna and Oncotype DX with emphasis on menopausal status and lymph node involvementGiulia Cursano, Nicola Fusco, Mariia Ivanova et al.|ESMO Open|2025Cited by 0